Pharming Group N.V. (PHAR)
NASDAQ: PHAR · Real-Time Price · USD
16.31
0.00 (0.00%)
At close: Mar 27, 2026, 4:00 PM EDT
16.35
+0.04 (0.25%)
After-hours: Mar 27, 2026, 5:31 PM EDT
Pharming Group Stock Forecast
Stock Price Forecast
The 2 analysts that cover Pharming Group stock have a consensus rating of "Strong Buy" and an average price target of $39, which forecasts a 139.12% increase in the stock price over the next year. The lowest target is $37 and the highest is $41.
Price Target: $39 (+139.12%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Pharming Group stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $37 | Strong Buy | Reiterates | $37 | +126.85% | Mar 24, 2026 |
| Oppenheimer | Oppenheimer | Buy Reiterates $42 → $41 | Buy | Reiterates | $42 → $41 | +151.38% | Mar 13, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $37 | Strong Buy | Reiterates | $37 | +126.85% | Mar 21, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $37 | Strong Buy | Reiterates | $37 | +126.85% | Mar 20, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $30 → $39 | Buy | Maintains | $30 → $39 | +139.12% | Mar 14, 2025 |
Financial Forecast
Revenue This Year
413.89M
from 376.13M
Increased by 10.04%
Revenue Next Year
425.05M
from 413.89M
Increased by 2.70%
EPS This Year
0.04
from 0.00
Increased by 888.80%
EPS Next Year
0.04
from 0.04
Decreased by -6.77%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 477.0M | 557.8M | |||
| Avg | 413.9M | 425.1M | |||
| Low | 333.7M | 257.2M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 26.8% | 34.8% | |||
| Avg | 10.0% | 2.7% | |||
| Low | -11.3% | -37.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| High | 0.05 | 0.07 | ||
| Avg | 0.04 | 0.04 | ||
| Low | 0.01 | -0.01 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| High | 1,265.0% | 75.2% | ||
| Avg | 888.8% | -6.8% | ||
| Low | 145.0% | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.